Dry Eyes Chronic

3

Review clinical trials related to Dry Eyes Chronic. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye

Prospective, multicenter, randomized, vehicle-controlled, double-masked, study of CAM-101 topical ophthalmic solution compared to vehicle control followed by crossover to long-term follow-up open-label treatment with CAM-101 for one year.

Participants needed: 475
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Cambium Bio LimitedUpdated: Jun 12, 2026
Eligibility criteria

Male or female subjects who at the time of consent are 18 years of age or older,... [+10]

Any abnormal lid anatomy or blinking function in either eye. [+27]

Status: Not yet recruiting

Switching From Xiidra to TRYPTYR

To determine the efficacy of switching participants who are being treated with Xiidra to acoltremon 0.003%. Hypothesis: Switching to acoltremon 0.003% will greatly improve the signs and symptoms of participants who were being treated with Xiidra at 28 days post-treatment compared to baseline.

Participants needed: 100
Trial details
Phase: Phase 4Age: 18-99Biological sex: AllType: InterventionalSponsor: Southern College of OptometryUpdated: Dec 5, 2025
Eligibility criteria

Adults ≥18 years of age. [+5]

Have a systemic health condition that is known to alter tear film physiology (e.... [+10]

Status: Not yet recruiting

Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.

This is a phase I clinical study to evaluate the safety and tolerability of PRO-190 ophthalmic solution through the incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), changes in ocular surface integrity, changes in the ocular comfort index (OCI) score, and IOP measurement compared to Systane Ultra®.

Participants needed: 32
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Laboratorios Sophia S.A de C.V.Updated: Mar 19, 2025
Eligibility criteria

Having the ability to voluntarily give their signed informed consent. [+8]

History of hypersensitivity to any of the components of the drugs under investig... [+17]